Loading...
Cellyan Biotechnology Co., Ltd
HKPD•NASDAQ
Healthcare
Medical - Pharmaceuticals
$0.69
$-0.00(-0.44%)
U.S. Market is Open • 14:23Cellyan Biotechnology Co., Ltd (HKPD) AI-Powered Stock Analysis
See how Cellyan Biotechnology Co., Ltd scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerCellyan Biotechnology Co., Ltd (HKPD) Stock Overall Grade
Cellyan Biotechnology Co., Ltd’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Cellyan Biotechnology Co., Ltd's overall stock rating.
Forecast
C+Score
52/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
58/100Key Ratios
BScore
67/100Sector Comparison
A+Score
100/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
95/100Analyst Consensus
C+Score
50/100Cellyan Biotechnology Co., Ltd (HKPD) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 52/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (58/100, C+) highlight its stability, while Key Ratios (67/100, B) and Sector Comparison (100/100, A+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (95/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Cellyan Biotechnology Co., Ltd stock grade, including financials, comparisons, and forecasts.